ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.65
0.00%
US Tech 100
21,213.60
0.73%
S&P 500
6,051.25
-0.54%
US Dollar vs CAD
1.42196
0.00%
Bitcoin
100,402.69
0.34%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alvontech (ALVO)

  7. Alvontech (ALVO) News

ALVO

Alvontech (ALVO)

Alvontech
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALVO
DateTimeSourceHeadlineSymbolCompany
11/13/20243:05PMGlobeNewswire Inc.Alvotech Reports Financial Results for the First Nine Months of 2024NASDAQ:ALVOAlvontech
11/07/20247:00AMGlobeNewswire Inc.Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024NASDAQ:ALVOAlvontech
11/04/20246:00AMGlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)NASDAQ:ALVOAlvontech
10/30/20247:30AMGlobeNewswire Inc.Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
10/25/20247:00AMGlobeNewswire Inc.Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024NASDAQ:ALVOAlvontech
10/22/20246:00AMGlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
10/10/20244:00AMGlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®NASDAQ:ALVOAlvontech
09/25/20244:00AMGlobeNewswire Inc.Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®NASDAQ:ALVOAlvontech
08/26/20248:14AMGlobeNewswire Inc.Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ALVOAlvontech
08/16/20244:57AMIH Market NewsH&R Block Shares Surge 10% on Profit and Dividend Boost, Applied Materials Drops 3% Despite Strong Earnings, Latest in EarningsNASDAQ:ALVOAlvontech
08/15/20243:15PMGlobeNewswire Inc.Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024NASDAQ:ALVOAlvontech
08/15/20245:09AMIH Market NewsU.S. Futures Rise on Easing Inflation, Oil Prices RiseNASDAQ:ALVOAlvontech
08/15/20243:30AMGlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)NASDAQ:ALVOAlvontech
08/01/20243:02PMGlobeNewswire Inc.Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
07/22/20245:30AMGlobeNewswire Inc.STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across EuropeNASDAQ:ALVOAlvontech
07/11/20243:45AMGlobeNewswire Inc.Alvotech Announces Closing of Private Debt FinancingNASDAQ:ALVOAlvontech
07/02/20248:00AMGlobeNewswire Inc.Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®NASDAQ:ALVOAlvontech
07/01/20244:35PMGlobeNewswire Inc.Alvotech Issues New Shares to Holders of Convertible BondsNASDAQ:ALVOAlvontech
07/01/20244:10AMGlobeNewswire Inc.Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024NASDAQ:ALVOAlvontech
06/26/20243:50AMGlobeNewswire Inc.Alvotech Receives Conversion Notices for Majority of Convertible BondsNASDAQ:ALVOAlvontech
06/18/20243:01AMGlobeNewswire Inc.Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in EuropeNASDAQ:ALVOAlvontech
06/11/20243:00AMGlobeNewswire Inc.Alvotech and STADA add to strategic alliance through denosumab partnershipNASDAQ:ALVOAlvontech
06/07/20243:00AMGlobeNewswire Inc.Alvotech Announces Strategic Refinancing AgreementNASDAQ:ALVOAlvontech
05/29/20247:05AMGlobeNewswire Inc.Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024NASDAQ:ALVOAlvontech
05/21/20244:15PMGlobeNewswire Inc.Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateNASDAQ:ALVOAlvontech
05/21/20249:05AMBusiness WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
05/21/20247:00AMGlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
05/21/20246:13AMIH Market NewsU.S. Index Futures Open Lower Amid Nasdaq Record, Fed SpeechesNASDAQ:ALVOAlvontech
05/20/20247:25PMBusiness WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
05/20/20247:25PMGlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
 Showing the most relevant articles for your search:NASDAQ:ALVO

Your Recent History

BIT
UC92U9
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved